World Acceptance Earnings Preview


World Acceptance (NAS: WRLD) beat estimates by $0.07 cents last quarter and investors are hoping it can beat them again. The company will unveil its latest earnings on Wednesday, Jan. 25. World Acceptance is a small-loan consumer finance company, which offers short-term small loans, medium-term larger loans, related credit insurance products and ancillary products and services to individuals.

What analysts say:

  • Buy, sell, or hold?: Analysts strongly back World Acceptance, with three of four rating it a buy and the remainder rating it a hold. Analysts like World Acceptance better than competitor Nelnet overall. World Acceptance's rating hasn't changed over the past three months.

  • Revenue Forecasts: On average, analysts predict $139.6 million in revenue this quarter. That would represent a rise of 10.7% from the year-ago quarter.

  • Wall Street Earnings Expectations: The average analyst estimate is earnings of $1.32 per share. Estimates range from $1.25 to $1.39.

What our community says:
Most CAPS All-Stars are skeptical of WRLD prospects, with 61.8% assigning it an "underperform" rating. The community is split on the stock with 50.3% of Fools awarding it an "outperform" rating and 49.7% an "underperform" rating. Fools are skeptical of World Acceptance and haven't been shy with their opinions lately, logging 136 posts in the past 30 days. World Acceptance's bearish CAPS rating of one out of five stars falls short of the Fool community sentiment.

One final thing: If you want to keep tabs on World Acceptance movements, and for more analysis on the company, make sure you add it to your Watchlist.

At the time thisarticle was published Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.